LIVN vs. PEN, STVN, GKOS, BLCO, NARI, IRTC, TMDX, SLNO, INSP, and NVST
Should you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Bausch + Lomb (BLCO), Inari Medical (NARI), iRhythm Technologies (IRTC), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Inspire Medical Systems (INSP), and Envista (NVST). These companies are all part of the "medical equipment" industry.
LivaNova vs. Its Competitors
Penumbra (NYSE:PEN) and LivaNova (NASDAQ:LIVN) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.
In the previous week, Penumbra had 5 more articles in the media than LivaNova. MarketBeat recorded 8 mentions for Penumbra and 3 mentions for LivaNova. LivaNova's average media sentiment score of 1.73 beat Penumbra's score of 0.84 indicating that LivaNova is being referred to more favorably in the news media.
Penumbra has a net margin of 3.41% compared to LivaNova's net margin of -17.41%. LivaNova's return on equity of 13.67% beat Penumbra's return on equity.
Penumbra presently has a consensus price target of $302.40, indicating a potential upside of 22.10%. LivaNova has a consensus price target of $59.29, indicating a potential upside of 27.06%. Given LivaNova's stronger consensus rating and higher probable upside, analysts plainly believe LivaNova is more favorable than Penumbra.
88.9% of Penumbra shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 5.0% of Penumbra shares are held by insiders. Comparatively, 0.3% of LivaNova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
LivaNova has higher revenue and earnings than Penumbra. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.
Penumbra has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500.
Summary
Penumbra and LivaNova tied by winning 8 of the 16 factors compared between the two stocks.
Get LivaNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LivaNova Competitors List
Related Companies and Tools
This page (NASDAQ:LIVN) was last updated on 7/9/2025 by MarketBeat.com Staff
